Premium
Do all angiotensin II type 1 receptor blockers have the same beneficial effects?
Author(s) -
Miura S,
Saku K
Publication year - 2007
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/sj.bjp.0707324
Subject(s) - pharmacology , angiotensin receptor blockers , angiotensin ii , receptor , medicine , chemistry , endocrinology , renin–angiotensin system , blood pressure
Angiotensin II type 1 (AT 1 ) receptor blockers (ARBs) are highly selective for the AT 1 receptor, which is a member of the G protein‐coupled receptor superfamily (GPCRs), and block the diverse effects (hypertension, hypertrophy, heart failure, proteinuria etc.) of angiotensin II. Many ARBs are in clinical use and have been shown to be safe and effective. Over the past several years, reports have discussed the different degrees of the beneficial effects of ARBs. As ARBs do not all have the same effects, the benefits conferred by ARBs may not be class effects. These different effects may be due to differences in the molecular characteristics of ARBs. The results reported by Le et al . in this issue highlight the different characteristics of two ARBs, olmesartan and telmisartan, and suggest that the higher degree of insurmountability, slower dissociation, and higher affinity of olmesartan compared to telmisartan for AT 1 receptors may help it to form a tight binding complex with this receptor. A better understanding of the different molecular mechanisms for each ARB could be useful for the treatment of patients. British Journal of Pharmacology (2007) 151 , 912–913; doi: 10.1038/sj.bjp.0707324